CREBBP and metabolic dysfunction-associated steatotic liver disease: Intriguingly, it was not until recently that the role of TA as a novel HATi was confirmed by Chung et al. through in vitro and in vivo non-alcoholic fatty liver disease (NAFLD) models, where TA was found to effectively inhibit the activities of p300, CBP, and PCAF; in particular, it inhibits p300 with the highest efficiency at an IC50 value of 3.886 mM (106) (Figures 3A,B).